» Articles » PMID: 31246892

Improved Renal Outcomes After Revascularization of the Stenotic Renal Artery in Pigs by Prior Treatment with Low-energy Extracorporeal Shockwave Therapy

Overview
Journal J Hypertens
Date 2019 Jun 28
PMID 31246892
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Revascularization does not restore renal function in most patients with atherosclerotic renal artery stenosis (RAS), likely because of inflammation and fibrosis within the stenotic kidney. Low-energy shockwave therapy (LE-SWT) stimulates angiogenesis in the stenotic kidney, but its ability to improve renal function and structure after revascularization remains unexplored. We tested the hypothesis that a LE-SWT regimen before percutaneous transluminal renal angioplasty (PTRA) would enable PTRA to restore renal function in hypercholesterolemic pigs with RAS (HC+RAS), and that this would be associated with attenuation of renal inflammation and fibrosis.

Methods And Results: Twenty-six pigs were studied after 16 weeks of HC+RAS, HC+RAS treated with PTRA with or without a preceding LE-SWT regimen (bi-weekly for 3 weeks), and controls. Single-kidney renal blood flow (RBF), glomerular filtration rate (GFR), and oxygenation were assessed in vivo using imaging 4 weeks after PTRA, and then inflammation and fibrosis ex vivo.Four weeks after successful PTRA, blood pressure fell similarly in both revascularized groups. Yet, stenotic-kidney GFR remained lower in HC+RAS and HC+RAS+PTRA (P < 0.01 vs. normal), but was improved in HC+RAS+PTRA+SW (P > 0.05 vs. normal). Furthermore, reduced inflammation, medullary fibrosis, and cortical hypoxia were only shown in swine stenotic kidneys pretreated with LE-SWT before PTRA 4 weeks later.

Conclusion: LE-SWT delivery before revascularization permitted PTRA to improve function and decrease cortical and medullary damage in the stenotic swine kidney. This study, therefore, supports the use of an adjunct SW pretreatment to enhance the success of PTRA in blunting loss of kidney function in experimental HC+RAS.

Citing Articles

Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) in Renal Diseases: A Review of Animal and Human Studies.

Skov-Jeppesen S, Petersen N, Yderstraede K, Jensen B, Bistrup C, Lund L Int J Nephrol Renovasc Dis. 2023; 16:31-42.

PMID: 36778197 PMC: 9912820. DOI: 10.2147/IJNRD.S389219.


Low-Intensity Shockwave Therapy (LI-ESWT) in Diabetic Kidney Disease: Results from an Open-Label Interventional Clinical Trial.

Skov-Jeppesen S, Yderstraede K, Jensen B, Bistrup C, Hanna M, Lund L Int J Nephrol Renovasc Dis. 2021; 14:255-266.

PMID: 34285548 PMC: 8286109. DOI: 10.2147/IJNRD.S315143.


Cell-based regenerative medicine for renovascular disease.

Lerman L Trends Mol Med. 2021; 27(9):882-894.

PMID: 34183258 PMC: 8403163. DOI: 10.1016/j.molmed.2021.06.004.


Renovascular Disease Induces Senescence in Renal Scattered Tubular-Like Cells and Impairs Their Reparative Potency.

Chen X, Kim S, Jiang K, Ferguson C, Tang H, Zhu X Hypertension. 2021; 77(2):507-518.

PMID: 33390051 PMC: 7808550. DOI: 10.1161/HYPERTENSIONAHA.120.16218.


It Comes As a Shock: Kidney Repair Using Shockwave Therapy.

Klomjit N, Lerman A, Lerman L Hypertension. 2020; 76(6):1696-1703.

PMID: 33131308 PMC: 7666065. DOI: 10.1161/HYPERTENSIONAHA.120.14595.


References
1.
Lin J, Zheng Y, Zhang Z, Shen W, Li X, Wei T . Suppression of Endothelial-to-Mesenchymal Transition by SIRT (Sirtuin) 3 Alleviated the Development of Hypertensive Renal Injury. Hypertension. 2018; 72(2):350-360. DOI: 10.1161/HYPERTENSIONAHA.118.10482. View

2.
Ebrahimi B, Gloviczki M, Woollard J, Crane J, Textor S, Lerman L . Compartmental analysis of renal BOLD MRI data: introduction and validation. Invest Radiol. 2011; 47(3):175-82. PMC: 3288694. DOI: 10.1097/RLI.0b013e318234e75b. View

3.
Abe Y, Ito K, Hao K, Shindo T, Ogata T, Kagaya Y . Extracorporeal low-energy shock-wave therapy exerts anti-inflammatory effects in a rat model of acute myocardial infarction. Circ J. 2014; 78(12):2915-25. DOI: 10.1253/circj.cj-14-0230. View

4.
Cabrita M, Jones L, Quizi J, Sabourin L, McKay B, Addison C . Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol. 2011; 5(6):517-26. PMC: 5528320. DOI: 10.1016/j.molonc.2011.10.004. View

5.
Lu B, Rajakumar S, Robson S, Lee E, Crikis S, dApice A . The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation. 2008; 86(12):1707-12. DOI: 10.1097/TP.0b013e31819022bc. View